focus -WSS

focus

author：explore 2025-09-29 02:46:40 - browse：1459

Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail, the developer of a multi-cancer screening test, which it bought over the objections of regulators in the U.S. and Europe in August 2021.

Illumina said the decision to spin Grail off followed a Friday decision of the U.S. Fifth Circuit Court of Appeals, which held that the merger was anti-competitive. It said that it would divest Grail either by selling it to another company or listing it on capital markets, consistent with an order from the European Commission, and that it aims to finalize the terms of the deal by the end of the second quarter of 2024.

The decision opens what should be the final chapter in one of the most disastrous attempted mergers in biotech history. Illumina, a storied name that had delivered investors strong returns over two decades, spun out Grail in 2016 in order to raise money to fund the company’s work. Then, it announced plans to re-acquire the firm for $7.1 billion in Sept. 2020.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Bernie brings in new pharma CEOs to talk drug prices

WSS

In Memoriam: Notable people who died in 2023

Global cancer cases to surge 77% by 2050, WHO report says

Top private equity targets in 2023: cardiology, clinical trials, lasers

Why Novartis is going to walk from its acquisition of MorphoSys

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Adopting new red light myopia treatments may be short

explore

focus

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

Readout LOUD: Venture capital, Gilead, and more M&A

United colonoscopy coverage change 'may cost lives,' doctors say

What’s missing from the debate over nursing home staff minimums

Heart attack and stroke risk calculators need revising

Bright Health sells Medicare Advantage business to Molina

Cancer drug shortages should be causing more outrage

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Medical leaders decry Supreme Court decision on affirmative action

Walensky prepares to leave CDC — and Congress — behind

focus

Padmanee Sharma of MD Anderson at center of lawsuit over credit

Apple is now the first public company to be valued at $3 trillion

Hepatitis C has a cure — but many Americans still lack access to it

Surgery pushed Ben Carson to fame

The CDC's new social media misinformation war

Why CTE doesn’t keep Americans from enjoying the Super Bowl

focus

knowledge

hotspot

knowledge